Ensoma
Boston
About Ensoma
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $258.0M
- Last round: Series Unknown (Sep 2025)
- Website: ensoma.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Life Science, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/ensoma-26138 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.